Redx is a biotech company focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease.
Clinical stage programme designed to unlock the potential of Wnt pathway blockade in oncology.
RXC007, a novel, orally active ROCK2 inhibitor is our next drug development candidate in fibrosis, to be developed as a best-in-class treatment with potential to address multiple diseases with underlying fibrosis, including IPF, NASH and diabetic nephropathy.
Exceptional capabilities in medicinal chemistry and translational science are the foundation of Redx. The Company has built an attractive portfolio of assets and has a strong proven track record of drug discovery and development. Over the past three years, it has delivered four major preclinical stage transactions, with further clinical and operational key milestones expected in the future. RXC004 is currently in a phase 1 clinical study in patients with advanced malignancies. The Company’s selective ROCK2 inhibitor, RXC007, is also expected to enter a phase 1 clinical study in H1 2021.